Literature DB >> 20938170

Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.

Thomas Schroeder1, Fabian Zohren, Christian Saure, Ingmar Bruns, Akos Czibere, Nelli Nancy Safaian, Roland Fenk, Rainer Haas, Guido Kobbe.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20938170     DOI: 10.1159/000320173

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  6 in total

Review 1.  Hypomethylating agents after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Guido Kobbe
Journal:  Stem Cell Investig       Date:  2016-11-28

2.  Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.

Authors:  Guiyun Song; Benigno C Valdez; Yang Li; Yan Liu; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2014-08-09       Impact factor: 5.742

Review 3.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

4.  Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Authors:  Sharyn D Baker; Eric I Zimmerman; Yong-Dong Wang; Shelley Orwick; Douglas S Zatechka; Jassada Buaboonnam; Geoffrey A Neale; Scott R Olsen; Eric J Enemark; Sheila Shurtleff; Jeffrey E Rubnitz; Charles G Mullighan; Hiroto Inaba
Journal:  Clin Cancer Res       Date:  2013-08-22       Impact factor: 12.531

5.  Salvage therapy for relapsed or refractory acute myeloid leukemia.

Authors:  James K Mangan; Selina M Luger
Journal:  Ther Adv Hematol       Date:  2011-04

Review 6.  Precision therapy for acute myeloid leukemia.

Authors:  Xue Yang; Jianxiang Wang
Journal:  J Hematol Oncol       Date:  2018-01-05       Impact factor: 17.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.